Last reviewed · How we verify
Enaroy (ENARODUSTAT)
Enarodustat (Enaroy), developed by Japan Tobacco, is a marketed drug for anemia in chronic kidney disease, positioning it in a niche but critical therapeutic area. Its key strength lies in its unique mechanism of action, inhibiting Egl nine homolog 1 to regulate erythropoietin production, distinguishing it from other treatments. The primary risk is the upcoming key patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | ENARODUSTAT |
|---|---|
| Sponsor | Japan Tabacco |
| Target | Egl nine homolog 1 |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Approved indications
- Anemia in chronic kidney disease
- Anemia of renal disease
Common side effects
Key clinical trials
- Correction of Anemia With Enarodustat in Non-dialysis Dependent Chronic Kidney Disease (PHASE4)
- Enarodustat Tablets at Different Initial Doses for Anemia in Non-dialysis CKD Patients (PHASE4)
- SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies (PHASE2)
- Study of SAL-0951 Compared to Recombinant Human Erythropoietin in Anemic Patients Receiving Maintenance Hemodialysis (PHASE3)
- Efficacy and Safety Study of SAL-0951 in the Treatment of Renal Anemia in Patients Receiving Peritoneal Dialysis (PHASE3)
- A Study to Evaluate Efficacy and Safety of JTZ-951 Compared to Darbepoetin Alfa in Korean Renal Anemia Patients Receiving Hemodialysis. (PHASE3)
- Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis (PHASE1)
- Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Enaroy CI brief — competitive landscape report
- Enaroy updates RSS · CI watch RSS
- Japan Tabacco portfolio CI